| Dr Shelly Dawn Faubion, DO | |
|
303 Se 4th St, Moore, OK 73160-6709 | |
| (405) 794-4664 | |
| (405) 794-2853 |
| Full Name | Dr Shelly Dawn Faubion |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 303 Se 4th St, Moore, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043292493 | NPI | - | NPPES |
| 100125330B | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3260 (Oklahoma) | Primary |
| 207P00000X | Emergency Medicine | 3260 (Oklahoma) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health Of Western Oklahoma | Weatherford, OK | Home health agency |
| Norman Regional | Norman, OK | Hospital |
| O U Medical Center | Oklahoma city, OK | Hospital |
| Integris Southwest Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Norman Regional Providers Primary Care | 5496837718 | 51 |
News Archive
Verisk Health, Inc., a global leader in healthcare data analytics, announced today signings in June and July of six new contracts for use of the Company's healthcare analytics, clinical resource management, risk assessment, and predictive modeling software.
There, the pitch by company CEO John R. Lewandowski, who opened with the line, "What if I told you I could save one million lives every year with just refrigerator magnets and a laser pointer?", got raves and a replay on Fortune Magazine/CNN online.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Ethicon Endo-Surgery, Inc. today announced the launch of EESadvancements.com, a new Web site designed to give surgeons advanced access to some of the company's newest surgical technology innovations before they reach full-scale release in the marketplace. The site also offers a collaborative environment where healthcare partners including surgeons, materials managers and OR Directors can share ideas on advancing the surgical continuum beyond minimally invasive procedures.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
› Verified 6 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Verisk Health, Inc., a global leader in healthcare data analytics, announced today signings in June and July of six new contracts for use of the Company's healthcare analytics, clinical resource management, risk assessment, and predictive modeling software.
There, the pitch by company CEO John R. Lewandowski, who opened with the line, "What if I told you I could save one million lives every year with just refrigerator magnets and a laser pointer?", got raves and a replay on Fortune Magazine/CNN online.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Ethicon Endo-Surgery, Inc. today announced the launch of EESadvancements.com, a new Web site designed to give surgeons advanced access to some of the company's newest surgical technology innovations before they reach full-scale release in the marketplace. The site also offers a collaborative environment where healthcare partners including surgeons, materials managers and OR Directors can share ideas on advancing the surgical continuum beyond minimally invasive procedures.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
› Verified 6 days ago
| Entity Name | Norman Regional Providers Primary Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548398274 PECOS PAC ID: 5496837718 Enrollment ID: O20080125000271 |
News Archive
Verisk Health, Inc., a global leader in healthcare data analytics, announced today signings in June and July of six new contracts for use of the Company's healthcare analytics, clinical resource management, risk assessment, and predictive modeling software.
There, the pitch by company CEO John R. Lewandowski, who opened with the line, "What if I told you I could save one million lives every year with just refrigerator magnets and a laser pointer?", got raves and a replay on Fortune Magazine/CNN online.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Ethicon Endo-Surgery, Inc. today announced the launch of EESadvancements.com, a new Web site designed to give surgeons advanced access to some of the company's newest surgical technology innovations before they reach full-scale release in the marketplace. The site also offers a collaborative environment where healthcare partners including surgeons, materials managers and OR Directors can share ideas on advancing the surgical continuum beyond minimally invasive procedures.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shelly Dawn Faubion, DO Po Box 1330, Norman, OK 73070-1330 Ph: (405) 307-6668 | Dr Shelly Dawn Faubion, DO 303 Se 4th St, Moore, OK 73160-6709 Ph: (405) 794-4664 |
News Archive
Verisk Health, Inc., a global leader in healthcare data analytics, announced today signings in June and July of six new contracts for use of the Company's healthcare analytics, clinical resource management, risk assessment, and predictive modeling software.
There, the pitch by company CEO John R. Lewandowski, who opened with the line, "What if I told you I could save one million lives every year with just refrigerator magnets and a laser pointer?", got raves and a replay on Fortune Magazine/CNN online.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Ethicon Endo-Surgery, Inc. today announced the launch of EESadvancements.com, a new Web site designed to give surgeons advanced access to some of the company's newest surgical technology innovations before they reach full-scale release in the marketplace. The site also offers a collaborative environment where healthcare partners including surgeons, materials managers and OR Directors can share ideas on advancing the surgical continuum beyond minimally invasive procedures.
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
› Verified 6 days ago
Nazanin Sara Hesami, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 320 N Service Rd, Moore, OK 73160 Phone: 405-794-4474 | |
Dr. Israel Becerra, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 S Telephone Rd Ste 250, Moore, OK 73160 Phone: 405-237-7500 | |
Nusrat Rumana, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 S Telephone Rd, Moore, OK 73160 Phone: 405-793-1188 | |
Dr. Sarah Elizabeth Cox, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1060 Sw 4th St, Moore, OK 73160 Phone: 405-378-5491 Fax: 405-378-5492 | |
Chandlar Maria Vazquez, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1060 Sw 4th St, Moore, OK 73160 Phone: 405-378-5491 Fax: 405-378-5492 | |
Kyle Fanning, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 Sw 34th St Ste 200, Moore, OK 73160 Phone: 405-793-1188 Fax: 405-793-0492 |